The coronavirus vaccine, developed by Oxford University in collaboration with the pharmaceutical company AstraZeneca, is likely to succeed. </p><div itemprop="articleBody"> When we started, there was an 80% chance of success, now it is only 50%, Adrian Hill, project manager in Oxford, told the British newspaper "Telegraph". <div class="relation-box"> <div class="relation-box-inner"> <div class="image-inner"> <a class="image-link" title="Очакват първите резултати от руската ваксина срещу коронавирус" target="_blank" href="https://www.actualno.com/interest/ochakvat-pyrvite-rezultati-ot-ruskata-vaksina-sreshtu-koronavirus-news_1465136.html" rel="noopener noreferrer"> <picture> <source srcset="https://i1.actualno.com/actualno_2013/upload/news/2020/05/21/0295975001590047036_1465136_144x110.webp?time=424" type="image/webp"> <source srcset="https://i1.actualno.com/actualno_2013/upload/news/2020/05/21/0295975001590047036_1465136_144x110.jpg" type="image/jpeg"> <img width="140" title="The first results of the Russian vaccine against coronavirus are expected" alt="The first results of the Russian vaccine against coronavirus are expected" class="image wp-post-image no-display appear lazyload" src="https://i1.actualno.com/actualno_2013/upload/news/2020/05/21/0295975001590047036_1465136_144x110.webp"/> </source></source></picture> </a> </div> <p> The first results of clinical trials of a Russian vaccine against the new coronavirus will appear in early July, Alexander G ... </div> </div> As the spread of the virus in the UK decreases and doctors register fewer and fewer infected, vaccine developers are unlikely to be able to use enough volunteers for the next stage of testing the new type of coronavirus vaccine.
If COVID-19 is not spread, volunteers will not be able to encounter the virus, which will not allow scientists to evaluate the effect of the new vaccine, which is being tested on humans since April 23.
The results of the first phase of clinical trials conducted in the UK will be announced in June. If they are successful, they will continue in other countries.
The most promising vaccines against coronavirus – there are important questions!
If all goes according to plan, in September 30 million people in Britain, that is, a little less than half of the population, will have access to the vaccine.
<div class="relation-box"> <div class="relation-box-inner"> <div class="image-inner"> <a class="image-link" title="Най-обещаващите ваксини срещу коронавируса - има важни въпросителни!" target="_blank" href="https://www.actualno.com/interest/naj-obeshtavashtite-vaksini-sreshtu-koronavirusa-ima-vajni-vyprositelni-news_1464580.html" rel="noopener noreferrer"> <picture> <source srcset="https://i1.actualno.com/actualno_2013/upload/news/2020/05/21/0747134001590047029_1464580_144x110.webp?time=424" type="image/webp"> <source srcset="https://i1.actualno.com/actualno_2013/upload/news/2020/05/21/0747134001590047029_1464580_144x110.jpg" type="image/jpeg"> <img width="140" title="The most promising vaccines against coronavirus - there are important questions!" alt="The most promising vaccines against coronavirus - there are important questions!" class="image wp-post-image no-display appear lazyload" src="https://i1.actualno.com/actualno_2013/upload/news/2020/05/21/0747134001590047029_1464580_144x110.webp"/> </source></source></picture> </a> </div> How promising are the two vaccines against the new coronavirus, which the world has been talking about the most lately - that of the American com ... </div> </div> Recall that the journal Nature has already indicated that one should not be too enthusiastic about the new vaccines.
As for the vaccine at Oxford University, it has shown excellent results in tests on monkeys, but in one aspect – it has protected them from pneumonia when infected with SARS-CoV-2. However, the virus remained active in the nasal cavity of the test animals – a total of 6 in number. A Chinese research team reported similar results earlier this month.
Peter Hottz, a medical scientist at Baylor College of Medicine in Houston, believes the findings so far are for a “moderate amount of antibodies” and that it appears the amount must be higher to protect against infection.
No one knows exactly how many antibodies protect against infection, said Michael Diamond, an immunologist at the University of Washington in St. Louis, Missouri. According to him, the issue can be solved by taking a higher dose of the vaccine, but more important is how long the established immunity lasts.
Sarah Gilbert, a virologist in Montana, USA, said of the Oxford vaccine that the monkeys were infected with a very large amount of SARS-CoV-2 and could explain the presence of the virus in the nasopharynx in both vaccinated and control animals. This virus may actually be inactive RNA that does not infect, she added. But this should be checked further – so as not to turn out that vaccinated with this vaccine can infect.